

# Jorge S Reis-Filho

List of PR Articles by Year  
in descending order

Source: [//exaly.com/author-pdf/8602794/publications.pdf](https://exaly.com/author-pdf/8602794/publications.pdf)

Version: 2025-02-01

166

PR articles

17,417

PR citations

10584

62

PR h-index

9871

126

g-index

190

documents

22966

doc citations

8143

72

h-index

32333

citing authors

#	ARTICLE	IF	PR CITATIONS
1	Chromothripsis-Mediated Small Cell Lung Carcinoma. <i>Cancer Discovery</i> , 2025, 15, 83-104.	25.6	34
2	The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance. <i>Nature Genetics</i> , 2024, 56, 60-73.	26.1	67
3	Somatic estrogen receptor $\hat{\pm}$ mutations that induce dimerization promote receptor activity and breast cancer proliferation. <i>Journal of Clinical Investigation</i> , 2024, 134, .	10.7	21
4	Image-based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immunology Biomarker Working Group on Breast Cancer. <i>Journal of Pathology</i> , 2024, 262, 271-288.	5.0	14
5	Regression-based Deep-Learning predicts molecular biomarkers from pathology slides. <i>Nature Communications</i> , 2024, 15, .	13.9	74
6	Converging and evolving immuno-genomic routes toward immune escape in breast cancer. <i>Nature Communications</i> , 2024, 15, .	13.9	12
7	A Genomics-Driven Artificial Intelligence-Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers <i>CDH1</i> Inactivating Mechanisms. <i>Cancer Research</i> , 2024, 84, 3478-3489.	0.6	17
8	Genotype-Directed Synthetic Cytotoxicity of ATR Inhibition with Radiotherapy. <i>Clinical Cancer Research</i> , 2024, 30, 5643-5656.	6.9	4
9	High-Sensitivity Mutation Analysis of Cell-Free DNA for Disease Monitoring in Endometrial Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 410-421.	6.9	44
10	Molecular Characterization of Acquired Resistance to KRASG12C EGFR Inhibition in Colorectal Cancer. <i>Cancer Discovery</i> , 2023, 13, 41-55.	25.6	108
11	Expanded genetic testing of GIST patients identifies high proportion of non-syndromic patients with germline alterations. <i>Npj Precision Oncology</i> , 2023, 7, .	6.7	48
12	Biological insights and novel biomarker discovery through deep learning approaches in breast cancer histopathology. <i>Npj Breast Cancer</i> , 2023, 9, .	6.5	47
13	Overcoming the challenges to implementation of artificial intelligence in pathology. <i>Journal of the National Cancer Institute</i> , 2023, 115, 608-612.	4.7	54
14	Dramatic, durable response to therapy in gBRCA2-mutated pancreas neuroendocrine carcinoma: opportunity and challenge. <i>Npj Precision Oncology</i> , 2023, 7, .	6.7	6
15	A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 3101-3109.	6.9	10
16	Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results. <i>Nature Medicine</i> , 2023, 29, 1400-1411.	39.5	81
17	Rare subtypes of triple negative breast cancer: Current understanding and future directions. <i>Npj Breast Cancer</i> , 2023, 9, .	6.5	45
18	Clinicopathologic and genomic features of lobular like invasive mammary carcinoma: is it a distinct entity?. <i>Npj Breast Cancer</i> , 2023, 9, .	6.5	12

#	ARTICLE	IF	PR CITATIONS
19	Long-molecule scars of backup DNA repair in BRCA1- and BRCA2-deficient cancers. <i>Nature</i> , 2023, 621, 129-137.	38.7	33
20	Genomic analysis and clinical correlations of non-small cell lung cancer brain metastasis. <i>Nature Communications</i> , 2023, 14, .	13.9	46
21	Non-cell-autonomous cancer progression from chromosomal instability. <i>Nature</i> , 2023, 620, 1080-1088.	38.7	225
22	Pitfalls in machine learningâ€based assessment of tumorâ€infiltrating lymphocytes in breast cancer: A report of the International Immunoâ€Oncology Biomarker Working Group on Breast Cancer. <i>Journal of Pathology</i> , 2023, 260, 498-513.	5.0	43
23	Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immunoâ€Oncology Biomarker Working Group on Breast Cancer. <i>Journal of Pathology</i> , 2023, 260, 514-532.	5.0	37
24	Most large structural variants in cancer genomes can be detected without long reads. <i>Nature Genetics</i> , 2023, 55, 2139-2148.	26.1	32
25	Genomic characterization of small cell carcinomas of the uterine cervix. <i>Molecular Oncology</i> , 2022, 16, 833-845.	4.2	31
26	Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130. <i>Journal of the National Cancer Institute</i> , 2022, 114, 664-675.	4.7	77
27	Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome. <i>Clinical Cancer Research</i> , 2022, 28, 404-413.	6.9	25
28	Pathogenesis of Triple-Negative Breast Cancer. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2022, 17, 181-204.	31.4	504
29	<i>ATM</i> Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications. <i>Journal of the National Cancer Institute</i> , 2022, 114, 761-770.	4.7	8
30	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	34.1	524
31	Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression. <i>Oncogene</i> , 2022, 41, 1835-1850.	6.7	20
32	Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues. <i>Gynecologic Oncology</i> , 2022, 165, 239-247.	3.1	12
33	Recurrent <i>WWTR1</i><sc>S89W</sc> mutations and Hippo pathway deregulation in clear cell carcinomas of the cervix. <i>Journal of Pathology</i> , 2022, 257, 635-649.	5.0	7
34	LINC00355 regulates p27KIP expression by binding to MENIN to induce proliferation in late-stage relapse breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, .	6.5	11
35	Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers. <i>Npj Breast Cancer</i> , 2022, 8, .	6.5	23
36	Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer. <i>Nature Cancer</i> , 2022, 3, 723-733.	22.8	287

#	ARTICLE	IF	PR CITATIONS
37	Microsatellite Instabilityâ€“High Endometrial Cancers with <i>MLH1</i> Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles. <i>Clinical Cancer Research</i> , 2022, 28, 4302-4311.	6.9	54
38	Solid-basaloid variant of adenoid cystic carcinoma of the breast with near complete response to neoadjuvant chemotherapy. <i>Npj Breast Cancer</i> , 2022, 8, .	6.5	15
39	ER $\pm$ -LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance. <i>Npj Breast Cancer</i> , 2022, 8, .	6.5	23
40	Single-cell genomic variation induced by mutational processes in cancer. <i>Nature</i> , 2022, 612, 106-115.	38.7	122
41	Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer. <i>Nature Medicine</i> , 2022, 28, 2353-2363.	39.5	129
42	Pathogenic <i>ATM</i> Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 266-273.	4.7	61
43	The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas. <i>Molecular Oncology</i> , 2021, 15, 1024-1039.	4.2	35
44	Metaplastic carcinomas of the breast without evidence of epithelial differentiation: a diagnostic approach for management. <i>Histopathology</i> , 2021, 78, 759-771.	3.7	18
45	Ultraviolet radiation drives mutations in a subset of mucosal melanomas. <i>Nature Communications</i> , 2021, 12, .	13.9	35
46	Homologous recombination deficiency: how genomic signatures are generated. <i>Current Opinion in Genetics and Development</i> , 2021, 66, 93-100.	3.2	29
47	Genomic Alterations in <i>PIK3CA</i> -Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3K $\pm$ Inhibitors. <i>Cancer Research</i> , 2021, 81, 2470-2480.	0.6	34
48	Mesonephric and mesonephric-like carcinomas of the female genital tract: molecular characterization including cases with mixed histology and matched metastases. <i>Modern Pathology</i> , 2021, 34, 1570-1587.	4.9	106
49	Genomic profile of advanced breast cancer in circulating tumour DNA. <i>Nature Communications</i> , 2021, 12, .	13.9	90
50	TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, .	6.5	26
51	Genetic interactions among Brca1, Brca2, Palb2, and Trp53 in mammary tumor development. <i>Npj Breast Cancer</i> , 2021, 7, .	6.5	8
52	Genetic characterisation of adult primary pleomorphic uterine rhabdomyosarcoma and comparison with uterine carcinosarcoma. <i>Histopathology</i> , 2021, 79, 176-186.	3.7	6
53	Independent realâ€“world application of a clinicalâ€“grade automated prostate cancer detection system. <i>Journal of Pathology</i> , 2021, 254, 147-158.	5.0	152
54	Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer. <i>Gynecologic Oncology</i> , 2021, 161, 535-544.	3.1	29

#	ARTICLE	IF	PR CITATIONS
55	PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1274-1281.	3.6	12
56	Histologic and genomic features of breast cancers with alterations affecting the SWI/SNF (SMARC) genes. <i>Modern Pathology</i> , 2021, 34, 1850-1859.	4.9	8
57	Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma. <i>Npj Breast Cancer</i> , 2021, 7, .	6.5	75
58	Paired Tumor-Normal Sequencing Provides Insights Into the TP53-Related Cancer Spectrum in Patients With Li-Fraumeni Syndrome. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1751-1760.	4.7	15
59	Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies. <i>Npj Breast Cancer</i> , 2021, 7, .	6.5	13
60	The clinical behavior and genomic features of the so-called adenoid cystic carcinomas of the solid variant with basaloid features. <i>Modern Pathology</i> , 2021, 35, 193-201.	4.9	43
61	Ki67 Assessment in Breast Cancer: Are We There Yet?. <i>Journal of the National Cancer Institute</i> , 2021, 113, 797-798.	4.7	10
62	Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination. <i>Npj Breast Cancer</i> , 2021, 7, .	6.5	22
63	HER2+ breast cancers evade anti-HER2 therapy via a switch in driver pathway. <i>Nature Communications</i> , 2021, 12, .	13.9	76
64	Diverse alterations associated with resistance to KRAS(G12C) inhibition. <i>Nature</i> , 2021, 599, 679-683.	38.7	385
65	Pancreatoblastomas and mixed and pure acinar cell carcinomas share epigenetic signatures distinct from other neoplasms of the pancreas. <i>Modern Pathology</i> , 2021, 35, 956-961.	4.9	9
66	Immunohistochemical assessment of HRAS Q61R mutations in breast adenomyoepitheliomas. <i>Histopathology</i> , 2020, 76, 865-874.	3.7	29
67	Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary. <i>Nature Communications</i> , 2020, 11, .	13.9	53
68	Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity. <i>Modern Pathology</i> , 2020, 33, 1056-1064.	4.9	58
69	Acquisition of APOBEC Mutagenesis and Microsatellite Instability Signatures in the Development of Brain Metastases in Low-Grade, Early-Stage Endometrioid Endometrial Carcinoma. <i>JCO Precision Oncology</i> , 2020, , 1217-1223.	2.1	2
70	The genomic landscape of metastatic histologic special types of invasive breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, .	6.5	41
71	Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. <i>Nature Cancer</i> , 2020, 1, 1188-1203.	22.8	174
72	FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer. <i>Cancer Cell</i> , 2020, 38, 534-550.e9.	38.5	111

#	ARTICLE	IF	PR CITATIONS
73	Histologic Classification and Molecular Signature of Polymorphous Adenocarcinoma (PAC) and Cribriform Adenocarcinoma of Salivary Gland (CASG). <i>American Journal of Surgical Pathology</i> , 2020, 44, 545-552.	3.6	56
74	Unraveling tumor immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. <i>Nature Genetics</i> , 2020, 52, 582-593.	26.1	203
75	Oncogenic properties and signaling basis of the PAX8-GLIS3 fusion gene. <i>International Journal of Cancer</i> , 2020, 147, 2253-2264.	4.5	12
76	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, .	6.5	165
77	Pleomorphic adenomas and mucoepidermoid carcinomas of the breast are underpinned by fusion genes. <i>Npj Breast Cancer</i> , 2020, 6, .	6.5	37
78	Genomic profiling of primary and recurrent adult granulosa cell tumors of the ovary. <i>Modern Pathology</i> , 2020, 33, 1606-1617.	4.9	53
79	Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma. <i>Modern Pathology</i> , 2020, 33, 2221-2232.	4.9	31
80	ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. <i>Nature Genetics</i> , 2020, 52, 198-207.	26.1	202
81	Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. <i>Nature Cancer</i> , 2020, 1, 382-393.	22.8	140
82	Whole-Exome Sequencing Analysis of the Progression from Non-Low-Grade Ductal Carcinoma In Situ to Invasive Ductal Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 3682-3693.	6.9	66
83	Problematic breast tumors reassessed in light of novel molecular data. <i>Modern Pathology</i> , 2020, 34, 38-47.	4.9	35
84	Clonal relationship and directionality of progression of synchronous endometrial and ovarian carcinomas in patients with DNA mismatch repair-deficiency associated syndromes. <i>Modern Pathology</i> , 2020, 34, 994-1007.	4.9	40
85	Homologous recombination DNA repair defects in PALB2-associated breast cancers. <i>Npj Breast Cancer</i> , 2019, 5, .	6.5	49
86	How Did We Get There? The Progression from Ductal Carcinoma In Situ to Invasive Ductal Carcinoma. <i>Current Breast Cancer Reports</i> , 2019, 11, 175-184.	0.8	2
87	PAX8-GLIS3 gene fusion is a pathognomonic genetic alteration of hyalinizing trabecular tumors of the thyroid. <i>Modern Pathology</i> , 2019, 32, 1734-1743.	4.9	54
88	Assessment of HMGA2 and PLAG1 rearrangements in breast adenomyoepitheliomas. <i>Npj Breast Cancer</i> , 2019, 5, .	6.5	26
89	V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer. <i>Cancer Discovery</i> , 2019, 9, 1182-1191.	25.6	43
90	Secretory carcinoma of the breast: clinicopathologic profile of 14 cases emphasising distant metastatic potential. <i>Histopathology</i> , 2019, 75, 213-224.	3.7	63

#	ARTICLE	IF	PR CITATIONS
91	Genomic analysis of recurrences and high-grade forms of polymorphous adenocarcinoma. <i>Histopathology</i> , 2019, 75, 193-201.	3.7	16
92	Solid pseudopapillary neoplasms of the pancreas are dependent on the Wnt pathway. <i>Molecular Oncology</i> , 2019, 13, 1684-1692.	4.2	37
93	Massively parallel sequencing analysis of benign melanocytic naevi. <i>Histopathology</i> , 2019, 75, 29-38.	3.7	16
94	Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers. <i>Scientific Reports</i> , 2019, 9, .	3.5	39
95	Radiogenomics Analysis of Intratumor Heterogeneity in a Patient With High-Grade Serous Ovarian Cancer. <i>JCO Precision Oncology</i> , 2019, , 1-9.	2.1	18
96	High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. <i>Nature Medicine</i> , 2019, 25, 1928-1937.	39.5	630
97	Lobular Carcinomas <i>&lt;i&gt;In Situ&lt;/i&gt;</i> Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 674-686.	6.9	60
98	Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression. <i>Gynecologic Oncology</i> , 2019, 152, 11-19.	3.1	88
99	Recurrent <i>&lt;i&gt;MED12&lt;/i&gt;</i> exon 2 mutations in benign breast fibroepithelial lesions in adolescents and young adults. <i>Journal of Clinical Pathology</i> , 2019, 72, 258-262.	2.0	26
100	The Genomic Landscape of Mucinous Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 737-741.	4.7	80
101	Sclerosing epithelioid mesenchymal neoplasm of the pancreas—A proposed new entity. <i>Modern Pathology</i> , 2019, 33, 456-467.	4.9	14
102	Histologic spectrum of polymorphous adenocarcinoma of the salivary gland harbor genetic alterations affecting PRKD genes. <i>Modern Pathology</i> , 2019, 33, 65-73.	4.9	46
103	The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1030-1034.	4.7	113
104	Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases. <i>Cancer Research</i> , 2018, 78, 3112-3121.	0.6	72
105	Invasion in breast lesions: the role of the epithelial—stroma barrier. <i>Histopathology</i> , 2018, 72, 1075-1083.	3.7	36
106	Reliability of Whole-Exome Sequencing for Assessing Intratumor Genetic Heterogeneity. <i>Cell Reports</i> , 2018, 25, 1446-1457.	6.4	86
107	Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. <i>Cancer Cell</i> , 2018, 34, 893-905.e8.	38.5	444
108	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. <i>Cancer Cell</i> , 2018, 34, 427-438.e6.	38.5	863

#	ARTICLE	IF	PR CITATIONS
109	Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors. <i>Nature Communications</i> , 2018, 9, .	13.9	125
110	Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas. <i>Nature Communications</i> , 2018, 9, .	13.9	122
111	Breast Cancer Heterogeneity: Roles in Tumorigenesis and Therapeutic Implications. <i>Current Breast Cancer Reports</i> , 2017, 9, 34-44.	0.8	11
112	The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas. <i>Clinical Cancer Research</i> , 2017, 23, 3859-3870.	6.9	150
113	Myxoid fibroadenomas differ from conventional fibroadenomas: a hypothesis-generating study. <i>Histopathology</i> , 2017, 71, 626-634.	3.7	31
114	Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases. <i>Clinical Cancer Research</i> , 2017, 23, 4402-4415.	6.9	103
115	Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer. <i>Journal of Pathology</i> , 2017, 242, 165-177.	5.0	55
116	Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes. <i>Nature Communications</i> , 2017, 8, .	13.9	214
117	Phyllodes tumors with and without fibroadenoma-like areas display distinct genomic features and may evolve through distinct pathways. <i>Npj Breast Cancer</i> , 2017, 3, .	6.5	66
118	The Spectrum of Triple-Negative Breast Disease. <i>American Journal of Pathology</i> , 2017, 187, 2139-2151.	3.4	172
119	An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer. <i>Nature Medicine</i> , 2017, 23, 929-937.	39.5	170
120	Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast. <i>Npj Breast Cancer</i> , 2017, 3, .	6.5	79
121	Lack of <i>PRKD2</i> and <i>PRKD3</i> kinase domain somatic mutations in <i>PRKD1</i> wild-type classic polymorphous low-grade adenocarcinomas of the salivary gland. <i>Histopathology</i> , 2016, 68, 1055-1062.	3.7	26
122	Infiltrating epitheliosis of the breast: characterization of histological features, immunophenotype and genomic profile. <i>Histopathology</i> , 2016, 68, 1030-1039.	3.7	38
123	Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and <i>TERT</i> promoter hotspot mutations and <i>TERT</i> gene amplification as likely drivers of progression. <i>Journal of Pathology</i> , 2016, 238, 508-518.	5.0	127
124	Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring <i>TP53</i> somatic mutations. <i>Journal of Pathology</i> , 2016, 238, 677-688.	5.0	62
125	Resolving quandaries: basaloid adenoid cystic carcinoma or breast cylindroma? The role of massively parallel sequencing. <i>Histopathology</i> , 2016, 68, 262-271.	3.7	24
126	<i>PALB2</i> , <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS. <i>Journal of Medical Genetics</i> , 2016, 53, 800-811.	3.9	204

#	ARTICLE	IF	PR CITATIONS
127	Patient-derived xenograft (PDX) models in basic and translational breast cancer research. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 547-573.	7.2	243
128	Massively parallel sequencing analysis of synchronous fibroepithelial lesions supports the concept of progression from fibroadenoma to phyllodes tumor. <i>Npj Breast Cancer</i> , 2016, 2, .	6.5	32
129	<i>IDH2</i> Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity. <i>Cancer Research</i> , 2016, 76, 7118-7129.	0.6	121
130	Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology. <i>Modern Pathology</i> , 2016, 29, 476-488.	4.9	111
131	Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 4623-4633.	6.9	190
132	Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer. <i>Modern Pathology</i> , 2016, 29, 1292-1305.	4.9	76
133	Phyllodes tumours of the breast: a consensus review. <i>Histopathology</i> , 2016, 68, 5-21.	3.7	432
134	Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. <i>Npj Breast Cancer</i> , 2016, 2, .	6.5	170
135	The Genomic Landscape of Male Breast Cancers. <i>Clinical Cancer Research</i> , 2016, 22, 4045-4056.	6.9	136
136	Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family. <i>Modern Pathology</i> , 2016, 30, 69-84.	4.9	67
137	The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study. <i>Journal of Pathology</i> , 2015, 237, 166-178.	5.0	65
138	Are acinic cell carcinomas of the breast and salivary glands distinct diseases?. <i>Histopathology</i> , 2015, 67, 529-537.	3.7	50
139	<i>MED12</i> somatic mutations in fibroadenomas and phyllodes tumours of the breast. <i>Histopathology</i> , 2015, 67, 719-729.	3.7	91
140	Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas. <i>Journal of the National Cancer Institute</i> , 2015, 108, djv427.	4.7	206
141	Breast Cancer Genomics From Microarrays to Massively Parallel Sequencing: Paradigms and New Insights. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	4.7	84
142	Genomic landscape of adenoid cystic carcinoma of the breast. <i>Journal of Pathology</i> , 2015, 237, 179-189.	5.0	150
143	Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification. <i>Genome Biology</i> , 2015, 16, .	12.8	123
144	Mesothelin Expression in Triple Negative Breast Carcinomas Correlates Significantly with Basal-Like Phenotype, Distant Metastases and Decreased Survival. <i>PLoS ONE</i> , 2014, 9, e114900.	2.4	89

#	ARTICLE	IF	PR CITATIONS
145	PI3K Pathway Activation in High-Grade Ductal Carcinoma <i>In Situ</i> Implications for Progression to Invasive Breast Carcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 2326-2337.	6.9	45
146	Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations. <i>Genome Biology</i> , 2014, 15, .	8.2	129
147	Inference of Tumor Evolution during Chemotherapy by Computational Modeling and In Situ Analysis of Genetic and Phenotypic Cellular Diversity. <i>Cell Reports</i> , 2014, 6, 514-527.	6.4	254
148	Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. <i>Journal of Pathology</i> , 2014, 232, 553-565.	5.0	95
149	Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. <i>Nature Genetics</i> , 2014, 46, 1166-1169.	26.1	202
150	Metastatic breast carcinomas display genomic and transcriptomic heterogeneity. <i>Modern Pathology</i> , 2014, 28, 340-351.	4.9	92
151	Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. <i>Journal of Pathology</i> , 2012, 226, 84-96.	5.0	158
152	Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis. <i>Histopathology</i> , 2012, 60, .	3.7	58
153	Gene expression profiling in breast cancer: classification, prognostication, and prediction. <i>Lancet, The</i> , 2011, 378, 1812-1823.	52.8	674
154	Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. <i>Journal of Pathology</i> , 2010, 220, 562-573.	5.0	200
155	Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type. <i>Journal of Pathology</i> , 2010, 222, 282-298.	5.0	153
156	Breast cancer precursors revisited: molecular features and progression pathways. <i>Histopathology</i> , 2010, 57, 171-192.	3.7	310
157	Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast. <i>Modern Pathology</i> , 2010, 23, 951-960.	4.9	61
158	Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2010, 363, 1938-1948.	43.7	3,774
159	Histological types of breast cancer: How special are they?. <i>Molecular Oncology</i> , 2010, 4, 192-208.	4.2	469
160	Breast cancer molecular profiling with single sample predictors: a retrospective analysis. <i>Lancet Oncology, The</i> , 2010, 11, 339-349.	26.0	339
161	Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice. <i>Cancer Cell</i> , 2009, 15, 294-303.	38.5	554
162	Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype?. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 351-365.	3.0	82

#	ARTICLE	IF	PR CITATIONS
163	Microglandular adenosis or microglandular adenoma? A molecular genetic analysis of a case associated with atypia and invasive carcinoma. <i>Histopathology</i> , 2009, 55, 732-743.	3.7	51
164	Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type. <i>Modern Pathology</i> , 2009, 22, 1401-1414.	4.9	115
165	Histological and molecular types of breast cancer: is there a unifying taxonomy?. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 718-730.	75.5	387
166	Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. <i>Breast Cancer Research and Treatment</i> , 2008, 117, 273-280.	2.4	218